Regeneron Pharmaceuticals IncNASDAQ:REGN
- LAST PRICE969.1400
- TODAY'S CHANGE (%)-15.8800 (-1.6122%)
- Bid / Lots967.8600/ 4
- Ask / Lots969.8300/ 1
- Open / Previous Close974.8600 / 985.0200
- Day Range
- 52 Week Range
- Volume82,992
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | REGN |
|---|---|---|
| 09:32 ET | 8583 | 977.52 |
| 09:34 ET | 2914 | 978.39 |
| 09:36 ET | 6427 | 976.81 |
| 09:38 ET | 100 | 976.43 |
| 09:39 ET | 1800 | 973.52 |
| 09:41 ET | 309 | 974.54 |
| 09:43 ET | 400 | 972.875 |
| 09:45 ET | 100 | 972.44 |
| 09:48 ET | 800 | 972.9 |
| 09:50 ET | 810 | 973.135 |
| 09:52 ET | 734 | 973.175 |
| 09:54 ET | 649 | 973.18 |
| 09:57 ET | 800 | 972 |
| 09:59 ET | 135 | 971.8 |
| 10:01 ET | 200 | 971.81 |
| 10:03 ET | 232 | 969.44 |
| 10:06 ET | 2037 | 967 |
| 10:08 ET | 2164 | 967.15 |
| 10:10 ET | 614 | 967.405 |
| 10:12 ET | 1260 | 968.18 |
| 10:14 ET | 600 | 970.3999 |
| 10:15 ET | 300 | 968.695 |
| 10:19 ET | 430 | 969.145 |
| 10:21 ET | 623 | 968.035 |
| 10:24 ET | 100 | 968.9 |
| 10:26 ET | 100 | 968.725 |
| 10:28 ET | 200 | 968.03 |
| 10:30 ET | 1207 | 969.565 |
| 10:32 ET | 300 | 970.04 |
| 10:33 ET | 334 | 969.99 |
| 10:42 ET | 800 | 969.9734 |
| 10:44 ET | 452 | 970.4199 |
| 10:46 ET | 1839 | 968.1 |
| 10:48 ET | 800 | 969.92 |
| 10:50 ET | 1339 | 971.275 |
| 10:51 ET | 100 | 970.115 |
| 10:53 ET | 700 | 968.9 |
| 10:55 ET | 100 | 968.61 |
| 10:57 ET | 100 | 968.55 |
| 11:00 ET | 262 | 969.02 |
| 11:08 ET | 100 | 968.56 |
| 11:09 ET | 315 | 968.935 |
| 11:11 ET | 262 | 969.34 |
| 11:13 ET | 200 | 969.28 |
| 11:15 ET | 330 | 969.14 |
Today
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 29 minutes ago by Dow Jones
29 minutes ago by Dow JonesIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 9 hours ago by Dow Jones
9 hours ago by Dow Jones
Yesterday
May 26, 2024
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 11:06AM ET on Sunday May 26, 2024 by Dow Jones
11:06AM ET on Sunday May 26, 2024 by Dow JonesRegeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:02AM ET on Sunday May 26, 2024 by Dow Jones
11:02AM ET on Sunday May 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regeneron Pharmaceuticals Inc | 108.5B | 28.6x | +10.93% |
Vertex Pharmaceuticals Inc | 117.9B | 29.2x | +46.35% |
IQVIA Holdings Inc | 41.8B | 30.9x | +46.62% |
Moderna Inc | 63.9B | -9.8x | --- |
Biogen Inc | 31.7B | 27.2x | -18.14% |
ICON PLC | 26.5B | 39.2x | +4.68% |
Company Information
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Contact Information
- Headquarters
- 777 Old Saw Mill River RoadTARRYTOWN, NY, United States 10591
- Phone
- 781-370-5000
- Fax
- ---
Executives
- Co-Chairman of the Board, President, Chief Executive Officer, Founder
- Leonard Schleifer
- Co-Chairman of the Board, President, Chief Scientific Officer
- George Yancopoulos
- Chief Financial Officer, Senior Vice President - Finance
- Christopher Fenimore
- Executive Vice President, General Counsel, Secretary
- Joseph LaRosa
- Executive Vice President, General Manager - Industrial Operations and Product Supply
- Daniel Van Plew
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $108.5B |
|---|---|
Revenue (TTM) | $13.1B |
Shares Outstanding | 110.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.13 |
EPS | $33.86 |
Book Value | $237.41 |
P/E Ratio | 28.6x |
Price/Sales (TTM) | 8.3 |
Price/Cash Flow (TTM) | 25.3x |
Operating Margin | 29.40% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
